UrgoClean Ag

 

 

 

The UrgoClean Ag dressing is a sterile, non-woven pad, composed of hydro-desloughing, polyabsorbent cohesive fibres with a high absorption capacity (polyacrylate).

This dressing uses a hot melt process to bond the polyacrylate fibres arranged in a structured manner, parallel to the wound surface, giving UrgoClean Ag its specific absorption and wound residue draining properties, as well as its tensile strength.

The hydro-desloughing pad is coated with a silver-impregnated micro-adherent healing matrix (TLC: Lipido-Colloid Technology). This TLC-Ag matrix provides an antibacterial action and gels easily, aiding drainage of sloughy residue. In addition, it enables easy application and removal of the dressing.

 

PROPERTIES

In contact with the wound exudates, the TLC-Ag matrix forms a gel, creating a moist environment that promotes wound healing.

Simultaneously, the hydro-desloughing, polyabsorbent polyacrylate fibres absorb excess exudates, forming a gel. These hydro-desloughing fibres bind to the sloughy residues, absorbing and draining them in order to facilitate their elimination (autolytic debridement).

This binding and drainage of slough by the hydro-desloughing structure of UrgoClean Ag combined with its Silver healing matrix (TLC-Ag) thereby promotes the desloughing phase of sloughy wounds, and aids management of minor bleeding (particularly after mechanical or surgical debridement).

In addition, the Ag+ ions give UrgoClean Ag an antibacterial activity that could help reduce the local bacterial load. The Ag+ ion has broad-spectrum antimicrobial activity, covering Gram-negative and Gram-positive bacteria, as well as some yeasts. It is particularly effective against Staphylococcus aureus, MRSA, Streptococcus pyogenes and Pseudomonas aeruginosa (pyocyanic bacillus) the microorganisms most commonly implicated in infected wounds. The antibacterial activity of the dressing helps reduce odour caused by microorganisms present in the wound. UrgoClean Ag reduces the bacterial population of the biofilm within 24 hours and for 7 days (tested in vitro on S.aureus and P.aeruginosa).

Practicality: removal of the dressing in one piece due to the tensile strength of the hydro-desloughing fibres. The gel formed does not stick to the wound, making it easy to remove the dressing, painlessly or with only minor pain and with little or no damage to healed tissues.

INDICATIONS

UrgoClean Ag is indicated for the treatment of chronic exuding wounds (venous ulcers, pressure ulcers, diabetic foot ulcers) and acute wounds (burns, traumatic wounds, surgical wounds) at risk of or presenting signs of local infection, from the desloughing phase.

Contraindications:

  • Known sensitisation to silver.
  • UrgoClean Ag is not suitable for use as a surgical sponge for heavily bleeding wounds.
  • Do not combine UrgoClean Ag with hydrogen peroxide or organic mercury or hexamidine antiseptics.
  • Do not leave the dressing in place on the patient during Magnetic Resonance Imaging exams (MRI scan).

INSTRUCTIONS FOR USE

  1. Wound preparation:
  • Clean the wound with normal saline. In the event of prior use of an antiseptic (except contraindicated antiseptics), rinse the wound carefully with normal saline before applying the dressing.
  • The use of UrgoClean Ag does not dispense with the need for associated mechanical debridement when required.
  • During desloughing, the wound may appear to get larger due to gradual elimination of slough.
  1. Dressing application:
  • Remove the protective tabs.
  • Apply with the micro-adherent side of UrgoClean Ag in contact with the wound and its edges.

UrgoClean Ag can be cut using sterile scissors to adjust the dressing size to fit the wound if necessary.

  • If necessary, cover UrgoClean Ag with a secondary dressing suitable for the wound location and level of exudate.
  • Secure in place with a suitable bandage or tape.
  • Apply a compression bandage where prescribed.
  1. Dressing changes:

UrgoClean Ag should be changed every 1 to 2 days during the wound desloughing phase, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound. The maximum treatment duration with UrgoClean Ag is 1 month.

Precautions for use:

  • Treatment with UrgoClean Ag should be performed under medical supervision.
  • The use of this dressing does not dispense with the need for appropriate systemic antibacterial treatment for infected wounds, in accordance with local treatment protocols.
  • The silver-impregnated micro-adherent healing matrix (TLC-Ag) in UrgoClean Ag sticks to latex surgical gloves. It is therefore recommended that the dressing be handled carefully, avoiding any contact with the micro-adherent side, or using sterile tongs.
  • The concomitant use of other local treatments is not recommended.
  • Avoid contact with electrodes or conductive gels during electronic measurements, such as EEG or ECG recordings.
  • Clinicians and healthcare professionals must take into account the fact that data concerning the prolonged and repeated use of a silver dressing, particularly in children and newborn babies, are not very extensively documented.
  • In the absence of specific clinical data, the use of the UrgoClean Ag dressing during pregnancy or breastfeeding or in newborn or premature babies is not recommended.
  • UrgoClean Ag must not be used during hyperbaric oxygen chamber therapy without an oxygen mask (risk of combustion due to the presence of fat). This contraindication does not apply for hyperbaric oxygen chamber therapy with an oxygen mask if the oxygen concentration inside the chamber is less than 25% and if UrgoClean Ag is not applied on the area over which the mask is placed.
  • Sterile individual packaging, for single use. Reuse of a single-use dressing can lead to risks of infection.
  • Check that the sterility protector is intact before use. Do not use if the packaging is damaged.
  • Do not re-sterilise.
  • For disposal, refer to the existing protocol. Discard any unused parts of the dressing.

FORMATS

 

CLINICAL EVIDENCE

(1) Dalac S., Sigat L., Addala A. et al., Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016.

Other products

UrgoStart Plus Border

UrgoTul

UrgoK2

UrgoTul

 

UrgoTul is produced using Lipido-Colloid Technology, an exclusive patented innovation from Laboratoires Urgo.

UrgoTul is a non-adhesive, non-occlusive interface, composed of a polyester mesh impregnated with hydrocolloid particles (carboxymethylcellulose), paraffin oil, petrolatum and polymers.

 

 

 

PROPERTIES

In contact with wound exudates, the hydrocolloid particles gel and interact with the petrolatum component of UrgoTul to form a lipido-colloid gel in contact with the wound, creating a moist environment that promotes the healing process. UrgoTul has pro-healing efficacy, stimulating the proliferation of fibroblasts, key cells in the wound healing process(1,2,3).

Greasy in terms of its chemical composition without being greasy to the touch, UrgoTul does not stick to the wound or its edges: dressing changes are painless and atraumatic for the wound.

This results in some specific properties:

  • maintenance of a high level of greasy coating over time(4),
  • removal that causes no damage to newly formed tissue(5),
  • painless dressing changes for the patient.

INDICATIONS

UrgoTul is indicated in the treatment of:

  • Acute wounds (burns, dermal abrasions, traumatic wounds, postoperative wounds), chronic wounds (pressure ulcers, diabetic foot ulcers) at the granulation and epithelialisation stage.
  • Congenital epidermolysis bullosa wounds.

* Traumatic wound: wound treated with UrgoTul Border.

Flexible and highly conformable, UrgoTul is particularly indicated to cover irregular wounds or wounds in difficult locations, as well as for packing deep wounds.

Contraindications:

  • Known sensitivity to the dressing.

INSTRUCTIONS FOR USE

  1. Wound preparation:
  • Clean the wound using the conventional care protocol.
  • If an antiseptic has previously been used, rinse the wound carefully with normal saline before applying UrgoTul.

UrgoTul can be cut using sterile scissors to fit the dressing size to the wound and surrounding skin.

  1. Dressing application:
  • Remove the protective tabs of UrgoTul.
  • Apply UrgoTul directly to the wound.
  • Cover UrgoTul with a secondary dressing (sterile pads).
  • Secure the secondary dressing using a stretchy bandage, multi-stretch adhesive tape or a tubular mesh.
  1. Dressing changes:

UrgoTul dressings should be changed every 2 to 4 days, depending on the wound to be treated and its clinical condition. UrgoTul can be left in place for up to 7 days under multilayer compression in venous leg ulcers.

In congenital epidermolysis bullosa wounds, it should be changed every 1 to 3 days.

Precautions for use:

  • UrgoTul sticks to latex surgical gloves. It is therefore recommended that gloves be moistened with normal saline to facilitate handling of Urgotul in this case.
  • In the event of clinical signs of local infection, the doctor may decide to continue treatment using an antibacterial dressing.
  • In the event of deep, irregular or fistular wounds, leave part of the dressing visible and accessible outside the wound.
  • UrgoTul must not be used during hyperbaric oxygen chamber therapy without an oxygen mask (risk of combustion due to the presence of fat). This contraindication does not apply for hyperbaric oxygen chamber therapy with an oxygen mask if the oxygen concentration inside the chamber is less than 25% and if UrgoTul is not applied on the area over which the mask is placed.
  • Sterile individual packaging, for single use: reuse of a disposable dressing can lead to risks of infection.
  • Check that the sterility protector is intact before use. Do not use if the packaging is damaged.
  • Do not re-sterilise the dressing.

FORMATS

CLINICAL EVIDENCE

(1) Meaume S. Urgotul: a novel non-adherent lipidocolloid dressing. British Journal of Nursing. 2002, Vol 11, issue 16.

(2) Bernard FX et al. Effets d’un pansement lipidocolloïde sur la production de matrice extracellulaire. Journal des Plaies et Cicatrisations, 2007 (study conducted on Urgotul).

(3) Bernard FX et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloïd dressing. Journal of Wound Care, May 2005; 14 (5): 215-220 (study conducted on Urgotul).

(4) Le Berre. Y. Lurton et al., Pansments imprégnés : tulles/interfaces. CPC 2005 poster, Paris

(5) Meaume S et al. The importance of pain reduction through dressing selection in routine wound manager the MAPP study. Journal of Care 2004, vol 13, No 10, 409-413 (study conducted on UrgoTul).

Other products

UrgoStart Plus Border

UrgoClean Ag

UrgoK2

UrgoClean

UrgoClean, for complete and continuous cleansing

UrgoClean cleanses the wound of debris that impairs the healing process

 

PROPERTIES

  • Traps slough effectively (+50% lesions cleared compared to hydrofiber after 6W) and manages mild bleeding (1,2)
  • Absorbs exudate without maceration (3), protecting perilesional skin
  • Keeps the bottom of the lesion cleansed (maintenance debridement)(2,4)
  • Ensures atraumatic and painless care for the patient(2,5)

INDICATIONS

UrgoCleanis indicated for the treatment of exudative lesions in the desloughing phase (chronic lesions, acute lesions and cancerous lesions).

UrgoClean Rope is used for the treatment of cavitary lesions

 

INSTRUCTIONS FOR USE

  • Cleans the wound with physiological solution

  • Apply the micro-sticky side of the dressing in contact with the wound 
  • Use a secondary dressing depending on the volume of exudate and secure with a bandage or elastocompression therapy when prescribed

Change the dressing every 1-2 days at the beginning of the treatment and then up to 7 days, taking into account the exudate and the clinical state of the wound.

FORMATS

 

 

CLINICAL EVIDENCE

  1. Data on file Urgo, report n°88050-2009.
  2. Meaume S. et al., Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, Vol 23, No 3; March 2014, 105-116. 
  3. Meaume S. et al., Management of chronic wounds with an innovative absorbent wound dressing. J Wound Care, Vol 21, No 7; July 2012, 315-322. 
  4. Percival SL, et al. Slough and biofilm: removal of barriers to wound healing by desloughing. J Wound Care. 2015 Nov; 24(11):498,500-3,506-10. 
  5. Meaume et al., The importance of pain reduction through dressing selection in routine wound management: the MAPP study, Journal of Wound Care, 2004, Vol 13, No 10, 409-413.

Other products

UrgoClean Ag

UrgoTul Ag

UrgoTul

UrgoTul Ag

UrgoTul Ag è una medicazione non-aderente in poliestere conformabile con matrice all’argento TLC-Ag per combattere l’infezione locale.

 

 

BENEFICI

  • Riduzione rapida ed efficace della carica batterica (1)
  • Efficacia dimostrata in un RCT, con riduzione significativa dei segni di infezione locale facendo ripartire il processo di guarigione (2) 

 

INDICAZIONI

UrgoTul Ag è indicato per il trattamento delle lesioni a rischio di infezione o con segni di infezione locale:

  • ustioni
  • lesioni traumatiche
  • lesioni chirurgiche
  • lesioni degli arti inferiori
  • lesioni del piede diabetico 
  • lesioni da pressione 

En raison de son caractère non adhésif, le pansement UrgoTul Ag est recommandé dans le traitement des plaies présentant une peau péri-lésionnelle fragilisée.

 

ISTRUZIONI D'USO

1. Detergere la lesione con soluzione fisiologica

 

2. Applicare il lato micro-aderente della medicazione a contatto con la lesione

 

 

3. Utilizzare una medicazione secondaria 

 

 

Cambiare la medicazione ogni 1-3 giorni all’inizio del trattamento e poi fino a 7 giorni considerando l’essudato e lo stato clinico della lesione

FORMATI

 

PROVE CLINICHE

Efficacia clinicamente dimostrata:

2. Lazareth I et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization : results of a randomised controlled stydy. Wounds 2008 ; 20(6) :158-166.

1. Urgo TLC Silver range, Data on file.

Other products

UrgoTul